SavedAdd your journal

Journals / SDÜ Tıp Fakültesi Dergisi / 2021 / Cilt: 28 - Sayı: 1

Oxidative imbalance in autoimmune liver disease: evaluation of oxidant-antioxidant status and ischemia-modified albumin

Otoimmün karaciğer hastalığında oksidatif dengesizlik: oksidan-antioksidan durumun ve iskemi modifiye albüminin değerlendirilmesi

Inanc KARAKOYUN
Celal ULAŞOĞLU
Fatma Demet ARSLAN
Selin ONUR
Veli İYİLİKCİ
Banu Isbilen BASOK
Ayfer ÇOLAK
Pages
127–135
Publication Date
2021-03-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Serum TAS, OSI, TOS, IMA, and IMAR values were found to be significantly higher in the AILD group compared to controls (p=0.004,

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Current study evaluated the utility of total antioxidant status (TAS), oxidative stress index (OSI), total oxidant status (TOS), ischemia-modified albumin (IMA), and ischemia-modified albumin ratio (IMAR) as markers in autoimmune liver disease (AILD).
📊
Key Findings & Data:Material and Methods: The study included a total of 66 AILD patients, 22 with autoimmune hepatitis (AIH), 32 with primary biliary cholangitis (PBC), and 12 with AIH/PBC overlap syndrome, and 49 healthy controls.
💡
Conclusion & Impact:Results: Serum TAS, OSI, TOS, IMA, and IMAR values were found to be significantly higher in the AILD group compared to controls (p=0.004,
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Otoimmün karaciğer hastalığı · iskemi modifiye albumin · total antioksidan durum

Abstract

Objective: Current study evaluated the utility of total antioxidant status (TAS), oxidative stress index (OSI), total oxidant status (TOS), ischemia-modified albumin (IMA), and ischemia-modified albumin ratio (IMAR) as markers in autoimmune liver disease (AILD). Material and Methods: The study included a total of 66 AILD patients, 22 with autoimmune hepatitis (AIH), 32 with primary biliary cholangitis (PBC), and 12 with AIH/PBC overlap syndrome, and 49 healthy controls. Serum TAS, TOS, IMA, albumin (Alb), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBil), direct bilirubin (DBil), and 25-hydroxyvitamin D (25[OH]D) were analyzed. OSI was calculated as TOS/TAS and IMAR was derived from IMA and Alb. Results: Serum TAS, OSI, TOS, IMA, and IMAR values were found to be significantly higher in the AILD group compared to controls (p=0.004,

Özet

Amaç: Bu çalışmada, otoimmün karaciğer hastalığında (AILD) belirteç olarak total antioksidan durum (TAS), oksidatif stres indeksi (OSI), total oksidan durum (TOS), iskemi modifiye albumin (IMA) ve iskemi modifiye albumin oranının (IMAR) yararı değerlendirildi. Gereç ve Yöntem: Çalışma, 22'si otoimmün hepatit (AIH), 32'si primer biliyer kolanjit (PBC) ve 12'si AIH/PBC örtüşme sendromu olan toplam 66 AILD hastası ve 49 sağlıklı kontrol içermekteydi. Serum TAS, TOS, IMA, albumin (Alb), laktat dehidrojenaz (LDH), alkalen fosfataz (ALP), aspartat aminotransferaz (AST), alanin aminotransferaz (ALT), total bilirubin (TBil), direkt bilirubin (DBil) ve 25-hidroksivitamin D (25 [OH] D) analiz edildi. OSI, TOS/TAS olarak hesaplandı ve IMAR, IMA ve Alb'den türetildi. Bulgular: Serum TAS, TOS, OSI, IMA ve IMAR değerleri AILD grubunda kontrollere göre anlamlı olarak daha yüksekti (sırasıyla p=0.004,

🔖

Cite This Article

KARAKOYUN, I., ULAŞOĞLU, C., ARSLAN, F. D., ONUR, S., İYİLİKCİ, V., BASOK, B. I., ÇOLAK, A. (2021). Oxidative imbalance in autoimmune liver disease: evaluation of oxidant-antioxidant status and ischemia-modified albumin. SDÜ Tıp Fakültesi Dergisi, Cilt: 28 - Sayı: 1, 127–135. https://ajindex.com/articles/799440

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Floreani A, De Martin S, Secchi MF, Cazzagon N. Extrahepatic autoimmunity in autoimmune liver disease. European Journal of Internal Medicine 2019;59:1-7
  2. Hong-Ying Pan, Yi-Ning Dai, Ji-Na Zheng, Ke-Qing Shi, Sven Van Poucke, et al. National incidence of autoimmune liver diseases and its relationship with the human development index. Oncotarget 2016;7(29):46273–282
  3. Nayagam JS, Miquel R, Joshi D. Overlap Syndrome with Autoimmune Hepatitis and Primary Sclerosing Cholangitis. European Medical Journal Hepatology 2019;7(1):95-104
  4. Liberal R, Grant CR. Cirrhosis and autoimmune liver disease: Current understanding. World Journal of Gastroenterology 2016;8(28):1157-68
  5. Czaja AJ. Autoimmune liver disease. Current Opinion in Gastroenterology 2009;25:215-22
  6. Penz-Österreicher M, Österreicher CH, Trauner M. Fibrosis in autoimmune and cholestatic liver disease. Best Practice & Research Clinical Gastroenterology 2011;25(2):245-58
  7. Moreira RK, Revetta F, Koehler E, Washington MK. Diagnostic utility of IgG and IgM immunohistochemistry in autoimmune liver disease. World Journal of Gastroenterology 2010; 16(4):453-7
  8. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World Journal of Gastroenterology 2008;14:3374-87
  9. Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Digestive Diseases and Sciences 2010;55(8):2144-61
  10. Zen Y, Notsumata K, Tanaka N, Nakanuma Y. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? Human Pathology 2007;38:1669–75
  11. Miyake Y, Iwasaki Y, Terada R, et al. Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatology Research 2007;37:801–5
  12. Zachou K, Muratori P, Koukoulis GK, Granito A, Gatselis N, et al. Review article: autoimmune hepatitis – its aetiopathogenesis, clinical features, diagnosis and management. Alimentary Pharmacology & Therapeutics 2013;38:887–913
  13. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, et al; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology 2009;50:291–308
  14. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, et al. American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660–78
  15. Ramachandran A, Jaeschke H. Oxidative Stress and Acute Hepatic